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Biomedical research (BMR) can be defi ned as systematic investigation 
aimed to develop or contribute to general knowledge in the health-related 
sciences.1 BMR includes studies designed to improve the body of scientifi c 
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information on a biological process or disease, 
as well as those designed to evaluate the 
safety, eff ectiveness, or usefulness of a medical 
product, procedure, or intervention.2  BMR is 
based on the scientifi c method (observation, 
formulation of a question, construction of a 
hypothesis, experimentation, data analysis, 
drawing conclusions and communication 
of results) and is divided into three main 
branches: basic research, clinical research and 
translational research.2,3
BMR has resulted in major discoveries 
that have led to marked progress in the health-
related sciences. For example, advances in 
public health (such as vaccine development, 
improvement in water quality and drainage, 
disease prevention programs, and eradication 
or near-eradication of certain diseases [e.g. 
smallpox and poliomyelitis]) have increased the 
worldwide life expectancy from approximately 
30 years at the beginning of the 19th century 
to more than 68 years today.4,5 
BMR not only impacts the health status of 
the world’s population but also has a positive 
and signifi cant economic eff ect. It promotes 
savings in the public sector, creates jobs, increases 
and improves the quality of the workforce, 
stimulates business development and reduces 
social confl icts by enhancing quality of life.6 
In 1995, the savings attributable to biomedical 
research in the United States were estimated 
to be at least 68 billion dollars.7 In that year, 
every dollar invested in BMR in the U.S. 
produced approximately $16 dollars in profi ts. 
In Latin America, a cost-benefi t analysis of a 
program to control Chagas disease (designed 
on the basis of fi ndings from epidemiological 
studies in 15 countries in Central and South 
America) found that there is a saving of $17 
dollars in health care expenditures and disability 
for every dollar invested in the prevention of 
this disease.8
Not surprisingly, the World Health 
Organization has described biomedical research 
as an investment and not an expense.9 By using 
the number of lives saved from 1970 to 1990 
because of BMR discoveries, and multiplying 
this number by the “monetary cost of life” ( or 
a “year of life “), a group of economists found 
that BMR produced ~$2.8 trillion per year (over 
100 dollars produced per dollar invested).10 
An additional economic benefi t of BMR at 
the institutional level is that the universities or 
hospitals in which BMR is conducted attract 
excellent students and talented professionals, 
which maintains and/or expands the recognition 
and leadership of the institution at the local, 
regional, and international level.
Unfortunately, BMR is not a priority 
for the governments of most Latin American 
countries.11 In 2011, Colombia only invested 
0.18% of its gross domestic product (GDP) 
on research and development, while Argentina 
invested 0.64%.12 Brazil, the leader in the region, 
invested 1.2%. Th ese fi gures contrast sharply 
with the United States, which invested 2.84% 
of its GDP in that area in the same year. Yet 
even in the latter country (the largest investor 
globally), BMR expenses are much lower than 
expected when we take into account the multiple 
benefi ts mentioned above.6,7,13 In 2009, the 
United States government (through the National 
Institutes of Health)  spent 47 billion dollars in 
BMR (or 1.9% of 2,472 billion dollars spent in 
health-related matters).14 Th is expense dropped 
substantially after the economic crisis, falling 
by nearly 12.5% in 2012.15 In 2013, with the 
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onset of drastic cuts in public spending (known 
as the “budget sequestration”), the total budget 
of the U.S. National Institutes of Health was 
reduced by 1.5 billion dollars, which limited 
further progress in BMR16 In spite of these 
diffi  culties, investment in BMR continues to 
be disproportionately higher in the United 
States than in Latin America.
Given limited government support in Latin 
America, health professionals, the general public, 
and their representatives must be educated about 
the importance of BMR. Th is is key to create 
promoters of this fi eld, as well as long-term 
policies based strictly on merit and scientifi c 
productivity. Such policies (often lacking in a 
region over-populated by politicians with “short-
term goals”) should foster and stimulate BMR 
through substantial and sustained investments 
in infrastructure, equipment, and human 
resources (including education, training, and 
professional development).
In 1937, Albert Szent-Györgyi (who 
discovered vitamin C) stated that “research 
consists of four elements: a brain to think 
with, a pair of eyes to observe, machines 
to measure, and –lastly– money.” Whereas 
researchers in the United States expect to have 
protected time and competitive salaries based 
on the quality and progress of their work (e.g., 
publications and grants, obtained through 
competitive applications to foundations and 
government entities), physicians or health 
care providers in Latin America are expected 
to conduct research without payment or with 
minimal compensation, while also carrying a 
heavy clinical load. As a result, many talented 
and ambitious young Latin Americans leave 
their countries in search of real opportunities 
to develop and eventually lead high-quality 
BMR.
To further promote BMR in Latin America 
would also require changing the current 
educational models of the vast majority of 
medical schools in our region, which often 
encourage memorization and obedience to 
dogma or existing guidelines, while stalling 
creative freedom or discordant thought (essential 
qualities in a researcher). For instance, extremely 
authoritarian systems frequently discourage 
bright students to express a divergent opinion, 
based on recent studies. In our experience, such 
systems view intellectually curious students 
as “problematic”, which in direct contrast to 
systems like that of the United States, in which 
medical students are encouraged to see all angles 
of a problem and express their opinion based 
on recently published articles, without fear of 
retaliation from their teachers or supervisors.
Latin American governments, operating 
through their ministries of health, should 
establish priorities in their agenda for BMR, 
according to the needs of their populations. 
Such agendas should aim to justly allocate and 
monitor funds devoted to high-quality studies 
(and not just those copying or replicating 
what has been done in developed countries). 
Educational institutions and medical centers 
(both public and private) should be essential 
participants in this process, which should aim 
to educate, train, and promote the careers of 
individuals devoted largely or exclusively to 
BMR. Th ese median and long-term objectives 
can be achieved with the support of governments, 
international foundations and organizations, 
as well as ethically appropriate collaborations 
with the pharmaceutical industry. Moreover, 
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we must train and retain talented leaders in 
BMR (by off ering adequate wages, resources, 
and infrastructure to develop unique research 
projects), who should expect to be promoted 
on the basis of merit and no other factors (such 
as family or political ties). By developing and 
committing to an appropriately ambitious 
agenda, BMR can fi nally be developed in our 
countries and thus achieve its main objective: 
to improve the health and quality of life of our 
populations.
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